COVID-19 Vaccine FAQs

COVID-19 Vaccination Information

UPDATED INFO: 5/20/2022

WV immunization law allows vaccines to be provided that follow the CDC’s recommended immunization schedule for adults, children, and adolescents (§15-12-3. Immunizations).  This is to notify you that the CDC has updated these recommendations related to COVID-19 vaccinations.

The FDA has authorized, Advisory Committee on Immunization Practices has met and recommended and the CDC has concurred with the recommendation to expand booster eligibility for ages 5-11 years and strengthen some recommendations.

Strengthened Recommendations:

It is now RECOMMENDED that:

  • 12 years and older who are immunocompromised
  • 50 years and older

Should receive a SECOND booster at least 4 months after the first booster.

Children ages 5-11 years:

It is now RECOMMENDED that:

  • Children ages 5-11 years receive a booster dose at least 5 months after their primary series

 

The information below is from before the 5/20/2022 update. We are awaiting the comprehensive updated graphics etc for the 5/20 revisions and will change below when this occurs.

COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised

Figure 1. COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised*

COVID-19 Vaccination Schedule.

Note: Timeline is approximate. Intervals of 3 months or fewer are converted into weeks per the formula “1 month = 4 weeks.” Intervals of 4 months or more are converted into calendar months.

*See Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised for schedule for people who are moderately or severely immunocompromised.

†An 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12–39 years. A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual’s higher risk for severe disease.

A booster dose is not currently authorized for people ages 5–11 years. For people ages 12–17 years, only Pfizer-BioNTech can be used. An mRNA COVID-19 vaccine is preferred over the Janssen COVID-19 Vaccine for booster vaccination of people ages 18 years and older.

§ People ages 18–49 years who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive an mRNA COVID-19 booster dose at least 4 months after the Janssen booster dose. People ages 50 years and older may choose to receive a second booster dose if it has been at least 4 months after the first booster dose.

Primary series for people who are not moderately or severely immunocompromised

mRNA COVID-19 vaccines

The mRNA COVID-19 vaccines are administered as a 2-dose primary series for most people. See Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised for recommendations specific to this population.

The same mRNA vaccine product should be used for all doses of the primary series (see Interchangeability of COVID-19 vaccine products).

Pfizer-BioNTech COVID-19 Vaccine is FDA-approved or FDA-authorized in people ages 5 years and older as a 2-dose primary series, with an interval of 3 weeks between doses (Table 2). Vaccination providers should ensure the correct age-appropriate formulation is administered based on the recipient’s age on the day of vaccination (Table 1).

Moderna COVID-19 Vaccine is FDA-approved or FDA-authorized in people ages 18 years and older as a 2-dose primary series, with an interval of 4 weeks between doses (Table 2).

Table 2. COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised*

TABLE 2: COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised*
Primary series vaccine manufacturer Age group Number of doses in primary series Number of booster doses Interval between 1st and 2nd primary doses Interval between primary series and booster dose
Pfizer-BioNTech 5–11 years 2 NA 3 weeks NA
Pfizer-BioNTech 12 years and older 2 1 3-8 weeks At least 5 months
Moderna 18 years and older 2 1 4-8 weeks At least 5 months
Janssen 18 years and older 1 1 NA At least 2 months

Abbreviation: NA = not applicable

*For the vaccination schedule for people who are moderately or severely immunocompromised, see Table 3

All people ages 12 years and older should receive 1 booster dose of a COVID-19 vaccine. Some adults may receive a second booster dose:

  • Adults ages 18-49 years: Those who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive an mRNA COVID-19 booster dose at least 4 months after the Janssen booster dose.
  • Adults ages 50 years and older: A second mRNA booster dose could benefit people ages 50 years and older, as they are at increased risk for severe COVID-19. People ages 50 years and older may choose to receive a second booster dose, if it has been at least 4 months after the first booster

An 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12–39 years. A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual’s higher risk of severe disease.

Considerations for intervals for mRNA COVID-19 vaccine primary series

mRNA COVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (Pfizer-BioNTech vaccine) or 4-week (Moderna vaccine) interval between the first and second dose. A 3- or 4-week interval continues to be the recommended interval for people who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about COVID-19 community levels or an individual’s higher risk for severe disease).

mRNA COVID-19 vaccines are safe and effective at the FDA-approved or FDA-authorized intervals, but a longer interval may be considered for some populations. While absolute risk remains small, the risk for myocarditis is higher for males ages 12-39 years, and this risk might be reduced by extending the interval between the first and second dose. Some studiespdf icon in adolescents (ages 12-17 years) and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. Extending the interval beyond 8 weeks has not been shown to provide additional benefit. There are currently no data available for children ages 11 years and younger. In summary, an 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 12-64 years, especially for males ages 12–39 years.

Janssen COVID-19 Vaccine

Although mRNA vaccines are preferred in most situations over the Janssen COVID-19 Vaccine, the Janssen COVID-19 Vaccine may be considered in some situations. See Contraindications and precautions and Safety considerations for Janssen COVID-19 Vaccine.

Janssen COVID-19 Vaccine is FDA-authorized for use in people ages 18 years and older. The primary series is a single dose. See Appendix D for additional information about completing schedules that have included use of the Janssen COVID-19 vaccine in people who are moderately or severely immunocompromised.

Booster doses for people who are not moderately or severely immunocompromised

All people ages 12 years and older should receive 1 booster dose of a COVID-19 vaccine after completion of the primary series (Table 2), even if they were younger than age 12 years at the time of the primary series. Some adults may receive a second booster dose.

mRNA COVID-19 vaccine primary series

  • Children ages 11 years and younger: Currently, COVID-19 vaccines are not authorized for use as a booster dose in this age group.
  • Adolescents ages 12–17 years: A single booster dose of Pfizer-BioNTech COVID-19 Vaccine is recommended at least 5 months after the second primary series dose, for a total of 3 doses.
  • Adults ages 18–49 years: A single booster dose is recommended at least 5 months after the second primary series dose, for a total of 3 doses. mRNA vaccines are preferred for the booster dose.
  • Adults ages 50 years and older: A booster dose is recommended at least 5 months after the second primary series dose, for a total of 3 doses. mRNA vaccines are preferred for the first booster dose. A second mRNA booster dose could benefit people ages 50 years and older, as they are at increased risk for severe COVID-19. People ages 50 years and older may choose to receive a second booster dose using an mRNA vaccine if it has been at least 4 months after the first booster dose, for a total of 4 doses.

Janssen COVID-19 primary series

  • Adults ages 18–49 years: A first booster dose is recommended at least 2 months after the single primary series dose, for a total of 2 doses. mRNA vaccines are preferred for the first booster dose. In addition, people who received Janssen COVID-19 Vaccine as both their primary series dose and first booster dose may receive a second booster dose using an mRNA vaccine at least 4 months after the first booster dose, for a total of 3 doses.
  • Adults ages 50 years and older: A booster dose is recommended at least 2 months after the single primary series dose for a total of 2 doses. mRNA vaccines are preferred for the first booster dose. A second mRNA booster dose could benefit people ages 50 years and older, as they are at increased risk for severe COVID-19. People ages 50 years and older may choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose, for a total of 3 doses.

Interval between primary series and booster doses(3)

First booster dose: The recommended interval is based on the product received for the primary series. In most people, the interval is:

  • At least 5 months after an mRNA 2-dose primary series or
  • At least 2 months after a Janssen single-dose primary series

Second booster dose: The recommended interval between the first booster dose and the second booster is at least 4 months, regardless of primary series or first booster dose product.

For information about schedules and booster doses for people who are moderately or severely immunocompromised, see Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised.

4-Day grace period

Doses administered up to 4 days before the minimum interval, known as the 4-day grace period, are considered valid. If a dose is administered prior to the 4-day grace period, see Appendix C. Doses administered at any time after the recommended interval are valid.

Interchangeability of COVID-19 vaccine products

In general, the same mRNA vaccine product (i.e., the same manufacturer) should be used for all doses in the primary series.

For people ages 18 years and older, in exceptional situations in which the mRNA vaccine product given for the first dose of the primary series cannot be determined or is not available, any available mRNA COVID-19 vaccine product may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 primary vaccination series.

In exceptional situations where a person received the first dose of an mRNA COVID-19 vaccine but is unable to complete the series with either the same or different mRNA COVID-19 vaccine (e.g., due to contraindication), a single dose of Janssen COVID-19 Vaccine may be considered at a minimum interval of 28 days from the mRNA COVID-19 vaccine dose if the person is age 18 years or older. People who receive Janssen COVID-19 Vaccine after a dose of an mRNA COVID-19 vaccine should be considered to have received a valid, single-dose Janssen primary series.

 

Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised

People with immunocompromising conditions or people who take immunosuppressive medications or therapies are at increased risk for severe COVID-19. Because the immune response following COVID-19 vaccination may differ in people who are moderately or severely immunocompromised at the time of vaccination, specific guidance for this population is provided. People who become moderately or severely immunocompromised after completing a 2-dose mRNA or single-dose Janssen COVID-19 Vaccine primary series should continue to follow the standard COVID-19 vaccination schedule. Use of mRNA vaccines is preferred.

COVID-19 vaccination schedule for people who are moderately or severely immunocompromised

Figure 2. COVID-19 vaccination schedule for people who are moderately or severely immunocompromised

COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised.

Note: Timeline is approximate. Intervals of 3 months or fewer are converted into weeks per the formula “1 month = 4 weeks”. Intervals of 4 months or more are converted into calendar months.

*An mRNA COVID-19 vaccine is preferred over the Janssen COVID-19 Vaccine for booster vaccination of people ages 18 years and older. For people ages 12–17 years, only Pfizer-BioNTech can be used. A booster dose is not authorized for people ages 5–11 years.

Only Pfizer-BioNTech or Moderna COVID-19 Vaccine should be used. See Appendix D for more information on vaccinating people who are moderately or severely immunocompromised and who received Janssen COVID-19 Vaccine for the primary series.

People ages 12 years and older may choose to receive a second booster dose using an mRNA COVID-19 vaccine if it has been at least 4 months after the first booster dose. For people ages 12–17 years, only Pfizer-BioNTech can be used.

Primary series for people who are moderately or severely immunocompromised

mRNA COVID-19 vaccines

A 3-dose primary series is recommended for people ages 5 years and older who are moderately or severely immunocompromised at the time of vaccination (Table 3). The same mRNA vaccine product should be used for all doses of the primary series (see Interchangeability of COVID-19 vaccine products).

Pfizer-BioNTech COVID-19 Vaccine (5 years and older): The second dose is administered 3 weeks after the first dose; the third dose is administered at least 4 weeks after the second dose.

Moderna COVID-19 Vaccine (18 years and older): The second dose is administered 4 weeks after the first dose; the third dose is administered at least 4 weeks after the second dose. The dose is 100 µg (0.5 ml [red cap vial]) for all doses in the primary series.

Janssen COVID-19 Vaccine

An mRNA vaccine is preferred, but a single primary Janssen vaccine dose can be used for people ages 18 years and older who are moderately or severely immunocompromised, followed by a second (additional) dose using an mRNA COVID-19 vaccine at least 4 weeks later (see Appendix D for additional information). If Moderna COVID-19 vaccine is used for the second dose, administer a 100 µg (0.5 ml [red cap vial]) dose.

Booster doses for people who are moderately or severely immunocompromised

Booster doses are recommended for all people ages 12 years and older after completion of primary vaccination (Table 3), even if they were younger than age 12 years at the time of the primary series.

mRNA COVID-19 vaccine primary series

A booster dose is recommended at least 3 months after the third dose in the primary series, for a total of four doses, preferably with an mRNA COVID-19 vaccine.

Special situation: For people who inadvertently received the booster dose before their third primary dose, regardless of type of vaccine received as the booster dose, administer a Pfizer-BioNTech vaccine or a Moderna vaccine (100 µg [0.5 mL, red cap vial]) as the fourth dose (third primary) at least 3 months after the third dose. See Appendix D for additional guidance.

A second booster dose using an mRNA vaccine could benefit people who are moderately or severely immunocompromised ages 12 years and older, as they are at increased risk for severe COVID-19. People ages 12 years and older may choose to receive a second booster dose using an age-appropriate mRNA vaccine if it has been at least 4 months after the first booster dose, for a total of 5 doses.

Janssen COVID-19 primary series

A booster dose is recommended at least 2 months after the second (additional) dose, for a total of 3 doses (1 Janssen vaccine dose followed by 1 additional mRNA vaccine dose, then 1 booster dose, preferably with an mRNA COVID-19 vaccine).

Special situation: Many recipients of Janssen COVID-19 Vaccine may have received a booster dose (Pfizer-BioNTech, Moderna [50 µg], or Janssen vaccine), without having had the second (additional) mRNA vaccine dose. In this situation, regardless of type and timing of vaccine received as the second dose, administer a Pfizer-BioNTech vaccine or a Moderna vaccine (100 µg [0.5 mL, red cap vial]) as the third (additional) dose at least 2 months after dose 2. See Appendix D for additional dose information for Janssen COVID-19 Vaccine recipients.

A second booster dose using an mRNA vaccine could benefit people who are moderately or severely immunocompromised, as they are at increased risk for severe COVID-19. These people may choose to receive a second booster dose using an mRNA COVID-19 vaccine if it has been at least 4 months after the first booster dose, for a total of 4 doses.

Table 3. COVID-19 vaccination schedule for people who are moderately or severely immunocompromised*

Table 3: COVID-19 vaccination schedule for people who are moderately or severely immunocompromised
Primary vaccination Age group Number of primary vaccine doses Number of booster doses Interval between 1st and 2nd dose Interval between 2nd and 3rd dose Interval between 3rd and 4th dose
Pfizer-BioNTech 5–11 years 3 NA 3 weeks At least 4 weeks NA
Pfizer-BioNTech 12 years and older 3 1* 3 weeks At least 4 weeks At least 3 months*
Moderna 18 years and older 3 1* 4 weeks At least 4 weeks At least 3 months*
Janssen 18 years and older 1 Janssen, followed by 1 mRNA 1* 4 weeks At least 2 months NA*

Abbreviation: NA = not applicable

*People ages 12 years and older may choose to receive a second booster dose using an mRNA COVID-19 vaccine if it has been at least 4 months after the first booster dose.

Description of moderate and severe immunocompromising conditions and treatment

Moderate and severe immunocompromising conditions and treatments include but are not limited to:

  • Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
  • Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment. Age or place of residence alone (e.g., residence in a long-term care settingexternal icon), independent of a patient’s medical condition, should not be used to determine the level of immune competence, as the balance of benefits and risks of a third primary dose for people who are not moderately or severely immunocompromised is currently unknown.

The new EUA Fact sheets for Health care Providers and Patient/Caregivers are listed below.  The information of the WVBOP.com will be update at the top of the COVID-19 vaccine FAQ page with a comprehensive update as additional information on these recommendation changes comes out.  Please check the page for additional updates related to this information https://www.wvbop.com/COVIDVaccineFAQ.asp

 

 

Pfizer (purple cap) Healthcare Provider (12 yrs and up)

Pfizer (grey cap) Healthcare Provider (16 yrs and up)

Pfizer (orange cap) Healthcare Provider (5-11 years)

Pfizer (purple and grey cap) Patient and Caregiver (12 years and up)

Pfizer (orange cap) Patient and Caregiver (5-11 years)

Moderna (labels with purple borders) Healthcare Providers

Moderna (labels with light blue borders) Healthcare Providers

Moderna Patient and Caregiver

Janssen (J&J) Healthcare Provider

Janssen (J&J) Patient and Caregiver

Pfizer (purple cap) Healthcare Provider (16 yrs and up)

Pfizer (grey cap) Healthcare Provider (16 yrs and up)

Pfizer (purple cap) Healthcare Provider (12 yrs and up)

Pfizer (grey cap) Healthcare Provider (12 yrs and up)

Pfizer (purple and grey cap) Patient and Caregiver (12 years and up)

 

UPDATED INFO 11/2/2021: Pfizer BioNTech Pediatric COVID-19 Vaccine (Orange Cap)

The Pfizer BioNTech Pediatric COVID-19 vaccine has been authroized for ages 5-11 years.  This is a NEW DRUG and the adult (purple cap) cannot be used in this age group.  The vaccine is arriving in WV and is being distributed to providers accross the state.  Additionally, the Federal Pharmacy Program is also receiving the Pediatric Pfizer product.  Please be VERY cautious and pay attention to detail as this product is different from the Adult drug.

WVBOP is following the PREP Act which allows registered immunizing pharmacists, plus appropriately trained pharmacy interns and certified pharmacy technicians to administer vaccines to ages 3 years and up.  The pharmacist can order (prescribe) the vaccine and at this time due to the Prep Act a prescription is not necessary.  Please make certain you have updated your Policy and Procedure manuals as required and have appropriate dosages of Epinephrine, diphenhydramine on hand for this age group in case an emergency arises.

WV has produced a short educational video (15 minutes) for the pediatric Pfizer BioNTech vaccine that will be available later today that any organization obtaining vaccine from the WV State supply is REQUIRED to view prior to administering any pediatric COVID-19 vaccine.  Others may view the video.  The link will be placed in the FAQ COVID-19 Vaccine section on the BOP website.

COVID-19 Vaccine Dosage and Administration

  • Children should receive the age-appropriate vaccine formulation regardless of their size or weight.
  • The Pfizer-BioNTech COVID-19 vaccine is supplied in a multiple dose (10 dose) vial with an orange cap and labeled with an orange border, is administered, after dilution with 1.3mL, as a primary series of 2 doses (0.2 mL each)
  • The formulation for children 5 to 11 years is a 2-dose vaccination series, given intramuscularly, recommended at least 3 weeks (21 days) apart

 

 

Pfizer Pediatrics Training Video Information :

 See below for link and instructions:

 

Instructions:

-Click the below link or copy and paste into your browser:

https://wvpca.webex.com/wvpca/k2/e.php?RCID=b02ba402006c4e1859699e2c2fcb53c6

 

-Click the “View” button

-Enter the following password:  COVID5-11Vaccine

-Click the “OK” button

-Enter your registration information and click “Register”

-You will be automatically directed to the training video, click the arrow in the center of the screen to play

 

The US Department of Health and Human Services has EXTENDED the authority for authorized persons (including pharmacists, pharmacy interns, qualified pharmacy technicians as explained below) to give vaccinations to those ages three and up per ACIP and FDA guidance. This is found here https://www.phe.gov/Preparedness/legal/prepact/Pages/COVID-Amendment-6.aspx It has been EXTENDED until October 1, 2024 or until withdrawn by US. DHHR.  This is distinct and separate from the WV Declaration of a State of Emergency. 

The FDA authorized and the CDC/ACIP recommended the Pfizer COVID-19 vaccine for adolescents age 12-15 years old.  Pharmacists may order AND administer while interns or pharmacy technicians may administer under the supervision of a registered immunizing pharmacist the Pfizer COVID-19 vaccine to ages 12-15 years per the PREP Act Amendment.

You can view the requirement indicating both FDA authorization AND being ordered according to ACIP’s COVID-19 vaccine recommendation at https://www.phe.gov/Preparedness/legal/prepact/Pages/4-PREP-Act.aspx

The CDC authorization can be found at https://www.cdc.gov/media/releases/2021/s0512-advisory-committee-signing.ht

1. To enroll your pharmacy as a COVID-19 WV Vaccine provider please email WV DHHR Chris Young at christopher.d.young@wv.gov and ask to have your pharmacy enrolled.

2.  Can my WV licensed pharmacy technician give COVID-19 vaccinations?

Yes.  The WV BOP voted to recognize the PREP Act Amendment linked here.

  1. The pharmacy technician must be CPhT.  He/she must complete one of the training programs listed here under the “PTCB-recognized Immunization Administration Education/Training Program”. The pharmacy technician does not have to have completed the PTCB Immunization Administration Assessment -Based Certificate Program, as this is not a requirement to meet the standard of the PREP Act. 
  2. The pharmacy technician must also complete an approved CPR program listed on the WV BOP website.
  3. These documents must be kept on file at the pharmacy where the technician is vaccinating.
  4. PLEASE REMEMBER:
  • This is ONLY during the COVID-19 State of Emergency.
  • The vaccination must be ordered by the supervising qualified pharmacist who is a registered immunizer
  • The supervising registered immunizing pharmacist must be readily and immediately available to the immunizing qualified pharmacy technicians.
  • The vaccine must be FDA-authorized or FDA-licensed.
  • In the case of a COVID-19 vaccine, the vaccination must be ordered and administered according to ACIP’s COVID-19 vaccine recommendation(s).
  • In the case of a childhood vaccine, the vaccination must be ordered and administered according to ACIP’s standard immunization schedule.
  • The qualified pharmacy technician must complete a minimum of two hours of ACPE- approved, immunization-related continuing pharmacy education during the relevant State licensing period(s).
  • The supervising registered immunizing pharmacist must comply with recordkeeping and reporting requirements of the jurisdiction in which he or she administers vaccines, including informing the patient’s primary care provider when available and submitting the required immunization information to the state or local immunization information system (vaccine registry).
  • The supervising registered immunizing pharmacist is responsible for complying with requirements related to reporting adverse events.
  • The supervising registered immunizing pharmacist must review the vaccine registry or other vaccination records prior to ordering the vaccination to be administered by the qualified pharmacy technician or State-authorized pharmacy intern.
  • The qualified pharmacy technician and State-authorized pharmacy intern must, if the patient is 18 years of age or younger, inform the patient and the adult caregiver accompanying the patient of the importance of a well-child visit with a pediatrician or other licensed primary-care provider and refer patients as appropriate.
  • The supervising registered immunizing pharmacist must comply with any applicable requirements (or conditions of use) as set forth in the CDC’s COVID-19 vaccination provider agreement and any other federal requirements that apply to the administration of COVID-19 vaccine(s).

3. .  Are there additional vaccinations that pharmacy technicians can administer?

According to the PREP Act, pharmacy technicians can administer

(1) vaccines that the Advisory Committee on Immunization Practices (ACIP) recommends to persons ages three through 18 according to ACIP's standard immunization schedule or

(2) seasonal influenza vaccine administered by qualified pharmacy technicians and interns that the ACIP recommends to persons aged 19 and older according to ACIP's standard immunization schedule; or

(3) FDA authorized or FDA licensed COVID -19 vaccines to persons ages three or older.

This PREP Act Amendment can be viewed here.

4.  Additional information regarding the CDC recommendations for Pfizer COVID-19 vaccination in 12-15 year olds:

Page Updated: 5/20/2022 11:43:00 PM